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ABSTRACT 
INFLUENCE OF CARDIOVASCULAR RISK FACTORS  
ON REMOTE ISCHEMIC PRECONDITIONING 
TIFFANY TRACHTE 
2016 
A powerful therapy against microvascular endothelial ischemia-reperfusion 
injury is remote ischemic preconditioning (rIPC), which triggers tissue protection 
by exposing a limb to small cycles of vascular occlusion. Animal models indicate 
that CVD risk factors reduce the protective benefits of ischemic conditioning. 
However, there are no human studies investigating how a burden of risk factors 
interferes with rIPC to prevent endothelial injury. The purpose of the present 
study was to determine the influence of risk factor burden on the capacity of rIPC 
to prevent endothelial reperfusion injury in humans.  
Twenty-two (age: 45±14 yr., BMI: 31±8 kg/m2) sedentary adults (12 lower 
burden: ≤2 risk factors; 10 raised burden: 3-5 risk factors) were studied. Digital 
arterial tonometry (EndoPAT 2000, Itamar Medical Inc.) was used to assess 
microvascular endothelial vasodilation during reactive hyperemia before and after 
65 min of left arm reperfusion injury (20 min brachial artery ischemia followed by 
45 min reperfusion) that was preceded by rIPC (right arm: 3X5 min 
ischemia/reperfusion). All subjects provided written informed consent according 
to the Internal Review Board guidelines at South Dakota State University.  
Repeated measures ANOVA was used to assess group differences 
between the reactive hyperemia index (RHI) before and after reperfusion injury. 
Statistical significance was set at P<0.05.  
ix 
 
 
In lower burden subjects, rIPC was able to prevent endothelial reperfusion 
injury. The RHI following endothelial injury increased from baseline by 23% (from 
2.1±0.4 to 2.5±0.5, P=0.072). In contrast, the RHI (baseline: 2.3±0.9) was 
significantly reduced by 25% despite induction of protection by rIPC (1.8±0.7) in 
the raised burden subjects (P=0.05). Between groups, the RHI after rIPC and 
endothelial injury was significantly different (P=0.008).  
Microvascular endothelial injury was prevented when preceded by rIPC in 
the lower burden subjects. Remote IPC failed to protect against endothelial injury 
in the raised risk burden subjects. CVD risk factors appear to disrupt the 
protective properties of ischemic conditioning in humans.  
 
 
1 
CHAPTER 1 
INTRODUCTION 
Myocardial ischemia-reperfusion (IR) injury occurs in the heart’s muscular 
wall tissue. Ischemia occurs when blood flow is blocked from tissue or an organ 
and reperfusion occurs when blood flow is restored. Injury to the tissue or organ 
can occur by both ischemia and/or reperfusion of the tissue/organ. The absence 
of blood prevents the tissue from receiving the necessary nutrients and oxygen to 
keep the tissue alive, while reperfusion causes injury due to the tissue/organs 
inability to deal with the sudden influx of blood, oxygen and nutrients. The causes 
of IR-injury are a direct result of vascular surgery, organ transplantation, and 
organ resection. Three consequences of myocardial IR-injury are myocardial 
stunning, microvascular dysfunction/”no-reflow”, and lethal reperfusion/cellular 
death.1 Myocardial stunning is abnormal functioning of the heart, present for 
approximately 2-14 days, and is reversible. Microvascular dysfunction or “no-
reflow” phenomenon happens when the ischemic tissue or organ is unable to 
reperfuse.2 The death of cardiomyocytes is considered lethal reperfusion injury 
and is not reversible. Ischemia between 1-5 minutes may cause rapid heart rate 
or fibrillation, 5-20 minutes may result in myocardial stunning and beyond 20 
minutes will result in tissue death.3 With respect to cardiovascular diseases 
(CVD), many people will undergo cardiac surgery to revascularize ischemic blood 
vessels. While these procedures are required for patient survival and to reduce 
complications from ischemia, many will experience further damage to the heart 
leading to death and disability.1 Although a patient greatly benefits from the 
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effects of cardiac surgery, the benefits are reduced because of myocardial 
ischemia reperfusion injury.1 
A large body of evidence has identified a promising new strategy to exploit 
the inherent cardioprotective properties of the heart. Cardioprotection against 
ischemia reperfusion can be accentuated by conditioning the heart to become 
more tolerant to an ischemic episode, a property known as ischemic 
preconditioning (IPC).4 Ischemic preconditioning is a type of conditioning 
stimulus applied before the onset of sustained ischemia.5 The conditioning 
stimulus can be applied directly to the target organ/tissue or it can be applied 
remotely, a process termed remote ischemic preconditioning (rIPC). Remote 
ischemic preconditioning, which involves subjecting a distant organ to brief, sub-
lethal bouts of ischemia followed by brief reperfusion, protects the targets organ 
against IR-injury.6 Experimental models have shown that preconditioning, either 
local or remote, can benefit many organs from the damage caused by IR-injury 
including the heart, kidney, brain, lung, and skeletal muscle.7 Currently, it is not 
entirely clear how conditioning strategies protect against IR-injury, but several 
studies suggest that multiple factors, such as protein kinases or signal 
transduction pathways, contribute to the protective benefits.7 However, despite 
these cardioprotective benefits, rIPC has not been translated into widespread 
clinical use. Many clinical trials are underway to determine the clinical efficacy of 
rIPC to protect the heart against IR-injury that inevitably accompanies common 
coronary revascularization procedures.8 Preliminary findings of these studies 
largely suggest a substantial clinical benefit of preconditioning to protect the 
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heart, but there are factors that appear to reduce its efficacy, particularly in the 
context of clustered cardiovascular risk factors.  
Cardiovascular risk factors include obesity, hypertension, insulin 
resistance, hyperglycemia, dyslipidemia, and aging. It is believed that the 
benefits of ischemic conditioning are decreased if a person possesses one or 
more of these risk factors. Preclinical studies have administered rIPC on animal 
subjects that were modified to obtain cardiovascular risk factors. These studies 
found that the benefits of rIPC were decreased.7 One study has been completed, 
on humans, which determined the correlation between aging and rIPC. The 
study’s results found that the benefits of rIPC on endothelial IR-injury were 
reduced.9 Collectively, animal data and one human study has consistently shown 
that the benefits of rIPC to protect against IR-injury are substantially reduced.7 It 
is currently unknown if similar findings occur in humans with other common CVD 
risk factors. If so, the clinical potential of ischemic conditioning strategies to 
protect the heart during coronary revascularization procedures may be adversely 
affected in the context of increased cardiovascular risk factors.  
 
Statement of the Problem 
While preclinical animal models of hypertension and hypercholesterolemia 
have shown reduced efficacy of IPC to protect against myocardial IR-injury, 
these findings have not been translated to humans. Increased CVD burden in 
clinical populations may lower the protective benefits of IPC which may adversely 
impact its clinical application to protect against IR-injury of the revascularized 
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heart. With the exception of advancing age, there are no studies investigating 
ischemic conditioning strategies on humans with clustered cardiovascular risk 
factors.  
 
Specific Aim 1: To determine the influence of increased cardiovascular risk 
burden on the capacity of rIPC to protect against endothelial IR-injury. 
 
H0: Elevated cardiovascular risk will diminish the capacity of rIPC to resist 
endothelial IR-injury. 
 
Independent Variables 
 Lower burden vs. Raised burden  
 Sham protocol vs. Experimental (rIPC) protocol 
 
Dependent Variables 
 Reactive Hyperemia Index (RHI) 
 
Delimitations: The study will be delimited to apparently healthy men and women 
of all ethnic and racial backgrounds, between 20-79 years of age, from Brookings 
County, South Dakota.  
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Limitations: We will not directly assess smooth muscle relaxation in this study, 
which does not eliminate the potential for impaired microvascular reactive 
hyperemia to be caused by reduced smooth muscle function. Separating the 
subjects into two risk factor groups is another limitation because of the inability to 
account for the effects caused by graded progression of multiple cardiovascular 
risk factors. Also, there are a lot of people who do not yet have CVD but are 
taking medications to treat their risk factors, particularly high blood pressure and 
cholesterol medications. We will not be studying these people which limits the 
application of our findings to groups not on treatment. 
 
Definition of terms 
 
Myocardial ischemia-reperfusion injury – the process of restoring blood flow 
(reperfusion) to the myocardium which was not receiving blood flow (ischemia) 
causing cellular dysfunction, damage or death.1 
 
Endothelial ischemia-reperfusion injury – the process of restoring blood flow 
(reperfusion) to endothelial tissue which was not receiving blood flow (ischemia) 
causing cellular dysfunction, damage or death.  
 
Ischemic conditioning – exposing an organ or tissue to repeated bouts of 
ischemia, intermittent with reperfusion, with the desire to condition and protect 
the exposed area to future ischemic episodes.  
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Ischemic preconditioning – ischemic conditioning completed prior to an 
ischemic episode. 
 
Remote ischemic preconditioning – ischemic conditioning completed on a 
body part located remotely from targeted tissue or organ. 
 
Endothelial function – when paracrine factors are in homeostasis and maintain 
normal vascular tone, blood fluidity, and limit vascular inflammation and smooth 
muscle cell proliferation.10 
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CHAPTER 2  
LITERATURE REVIEW 
The following literature review will discuss the clinical implications and 
causes of IR-injury with particular reference to the myocardium and vascular 
endothelium, the potential of ischemic conditioning to protect against reperfusion 
injury and proposed mechanisms to explain its cardioprotective benefits, and 
lastly, the impact of cardiovascular risk factors on the severity of IR-injury and 
how elevated CVD risk affects rIPC in humans.  
 
Clinical Implications of Ischemia-Reperfusion Injury 
 While prompt reperfusion of ischemic tissue is critical to preserve function 
and cell viability, it can increase the degree of injury beyond that attributed to 
ischemia alone. A major clinical problem, IR-injury affects all major organs, 
especially the brain, heart, liver and lungs.11 It can also induce localized damage 
to specific cells including the endothelial cells in vascular tissue, epithelial cells in 
the gastrointestinal region, and glomerular cells in the kidney.2,11 Ischemia – 
defined as diminished delivery of oxygen and nutrients to meet the metabolic 
demands of the cellular environment – can be caused by a variety of factors. The 
most prevalent of which is due to coronary artery disease that results in vessel 
occlusion in the heart. Indeed, the clinical consequences of ischemia manifest as 
myocardial infarction and stroke, which are the top leading causes of premature 
death worldwide. Acute vascular occlusion leading to ischemia requires quick 
restoration of blood flow via pharmacological and surgical intervention. In this 
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manner, IR-injury is a major limitation of current revascularization procedures, 
particularly percutaneous coronary angioplasty, coronary artery bypass graft 
surgeries, and even in heart transplantation. Although reperfusion is absolutely 
necessary to resupply the tissue with blood, it contributes to more extensive 
damage.12 Ultimately, IR-injury can lead to a heightened systemic inflammatory 
response, which, if unmanaged clinically can lead to multiple organ dysfunction, 
particularly in the heart which is often characterized by arrhythmias, myocardial 
stunning, and in severe cases premature mortality.12,13 Collectively, the 
mechanisms that attribute to IR-injury are varied and complex with implications 
that manifest differently in each individual person resulting in short term or fatal 
consequences. Risk factors such as diabetes, hypertension, and 
hypercholesterolemia, can may make a person more vulnerable to IR-injury. 
Based on the duration of ischemia, a variety of different clinical consequences 
can arise, particularly reperfusion arrhythmias, myocardial stunning, and 
endothelial dysfunction.  
 
Reperfusion arrhythmias 
The first clinical consequence of IR-injury, (and the least significant 
problem) in the heart is the development of myocardial arrhythmias, which often 
occur following 1-5 minutes of ischemia.14 Upon reperfusion, the homeostasis of 
the cellular environment is altered, causing abnormal ionic reactions with the 
previously ischemic environment. Some of these that have been shown to alter 
the electrical stability of the heart include reactive oxygen species (ROS), 
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increased Ca2+, and decreased pH contributing to reperfusion arrhythmias.15 
Frequent premature ventricular contractions within 90 minutes after reperfusion 
therapy, episodes of ventricular tachycardia, atrioventricular blocks are examples 
of reperfusion arrhythmias.16 It is thought that these electrical disturbances do not 
affect cardiac cell contractile performance and do not contribute to cell death. 
However, because the myocardium does not regenerate, these arrhythmias 
persist and may contribute to increased use of pharmacotherapy and 
hospitalization.17  
 
Myocardial Stunning 
A more severe clinical problem linked to IR-injury is known as myocardial 
stunning. Myocardial stunning is defined as reversible injury to cardiac myocytes 
that produces diminished contractile performance in the absence of cell death. It 
typically occurs when the duration of ischemia is between 5-20 minutes.17 This 
clinical problem occurs because of damage to cardiomyocytes during IR-injury 
which results in left ventricular contractile dysfunction without cell injury.14 
Myocardial stunning is generally a temporary condition and usually not fatal but it 
is a clinical concern because of the possibility of delaying reperfusion therapy.17  
 
Endothelial Dysfunction 
Reperfusion leads to intravascular inflammation and severe endothelial 
dysfunction.18 There is a rise in production of the vasoconstrictor endothelin-1 
and increased ROS that results in increased vasoconstriction and reduced blood 
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flow. Endothelial dysfunction also disturbs the balance between coagulation and 
anti-coagulation factors in the blood. Polymorphonuclear neutrophils are 
transported to the intravascular space from the interstitial space during ischemia, 
and such responses may contribute significantly to tissue damage during 
subsequent reperfusion.19 Moreover, Kharbanda and colleagues were one of first 
to show that 20 minutes of forearm ischemia impaired endothelium-mediated 
vasodilation. In 14 healthy men, blood flow responses to acetylcholine were 
blunted by ~50% following endothelial IR-injury.5 Furthermore, an experimental 
study done Pedersen and colleagues showed that endothelial IR-injury 
significantly diminishes tissue-type plasminogen activator (t-PA) release, a well-
established marker of vascular endothelial health and function, in healthy men.20 
From this evidence, it is important to recognize that IR-injury is ubiquitous and 
affects all cell types in the environment exposed to it. As described below under 
‘Mechanisms of IR-injury’, the aforementioned clinical implications of IR-injury 
arise from reductions in adenosine triphosphate (ATP), microvascular 
spasm/plugging/disturbance, increased oxidant stress, abnormal Ca2+ 
homeostasis, and mechanical failure/contractile protein structure.17 In the 
following section, I will discuss the mechanisms that lead to IR-injury resulting in 
the clinical consequences described above. 
 
Mechanisms of IR-Injury 
The mechanisms thought to cause IR-injury are complex and not 
completely understood. However, a large body of evidence from experimental 
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and clinical trials indicates that ATP depletion, calcium overload, oxidant stress, 
inflammation and coagulation are the main mechanisms of IR-injury. Each 
mechanism contributes uniquely to the debilitating aspects of IR-injury, as well as 
partaking in a vicious cycle amplifying each mechanism’s contributions to IR-
injury and exacerbating the conditions.  
 
ATP Depletion 
The heart almost exclusively relies on ATP production from oxidative 
phosphorylation as a result of glycolysis and beta-oxidation. During ischemia, 
oxidative phosphorylation ceases and the myocardial cell will resort for a very 
short period of time to anaerobic glycolysis. While the cellular environment’s pH 
has decreased because increased production and decreased removal of H+ ions, 
the availability of oxygen and nutrients have diminished. Without blood to transfer 
nutrients and oxygen, glucose or fatty acids cannot be catabolized to pyruvate 
which prevents acetyl-CoA from proceeding through the TCA cycle. Mitochondria 
within the affected cells, including endothelial cells and cardiomyocytes, are 
unable to resynthesize ATP and creatine phosphate resulting in further 
destructive consequences and cellular death caused by an overload of 
calcium.14,21  
 
Calcium Overload 
A major contributor of IR-injury results from calcium overload. During 
ischemia, myocardial pH drops because of increase anaerobic glycolysis that 
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produces greater concentrations of H+. As a result, the decrease in pH activates 
the Na+/H+ sarcolemma exchanger to increase removal of H+ from inside the cell 
to bring pH back to normal. Meanwhile, because of the drop in cellular ATP 
described above, the Na+/K+-ATPase is inhibited preventing the removal of Na+ 
from the cell. In turn, the Na+/Ca2+ exchanger, which normally extrudes Ca2+ from 
the cell, is reversed. Consequently, the Ca2+ concentration rises inside the cell 
contributing to cellular dysfunction and calcium overload.11 For example, a higher 
concentration of Ca2+ will activate protease enzymes that disrupts cell membrane 
integrity, and in myocardial cells contributes to hypercontracture, necrosis, and 
apoptosis.22 Subsequently, activated neutrophils and macrophages infiltrate the 
cell and stimulate inflammation, eventually causing further damage to the 
surrounding tissue.21 In addition, immediately upon reperfusion the increase in 
Ca2+ also overloads the mitochondria. This in turn opens the mitochondrial 
permeability transition pore (MTP) which uncouples oxidative phosphorylation 
leading to further ATP depletion and cellular death.11  
 
Oxidative Stress 
While ATP depletion and calcium overload drive the pathology of 
ischemia, rapid restoration of blood flow during reperfusion considerably 
increases the delivery of substrates to resume aerobic metabolism contributing to 
accelerated production of ROS. Oxidative stress is a major contributor to IR-
injury and occurs when an imbalance in the cellular environment exists between 
the ROS and antioxidants.23 Superoxide anion, hydroxyl radicals, hypocholorous 
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acid, hydrogen peroxide, and peroxynitrite, are the major sources of ROS formed 
macromolecules.14 For example, ROS damages the molecular structure of 
proteins, lipids, deoxyribonucleic acid (DNA) and disrupts cell membrane 
permeability. In addition, ROS stimulate expression of inflammatory cytokines 
and alter Ca2+ control in the mitochondria by opening the MTP.11,21 Taken 
together, it is clear from many experimental studies that increased generation of 
toxic levels of ROS plays an important role in the pathogenesis of reperfusion 
injury.  
 
Inflammation/Coagulation 
One main consequence of accelerated production of ROS during 
reperfusion is that they stimulate the expression of proinflammatory and 
procoagulant proteins; particularly tumor necrosis factor (TNF-α), interleukin (IL-6 
and IL-8), transforming growth factor beta (TGF-β) and nuclear factor-kappa B 
(NF-κB). Proinflammatory proteins, such as TNF-α, signal for leukocytes while 
further expression of inflammatory genes create adhesive endothelial cells. 
When NF-κB is activated, further expression of adhesion molecules and 
proinflammatory proteins attract monocytes, neutrophils and lymphocytes. 
Interleukin-6 and IL-8, contribute to the initial interaction between leukocytes and 
the endothelial cells as well as intracellular adhesion. The inflammation location 
is primed for leukocyte and platelet adhesion, which can eventually lead vascular 
dysfunction.23 
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In summary, IR-injury, especially in the heart and vasculature, is a major 
problem of coronary artery disease and undermines its treatment efficacy. While 
extensive experimental investigations targeting potential pharmacological and 
non-pharmacological approaches to limit IR-injury are underway, to date there is 
no effective treatment for it. However, a promising strategy to prevent or reduce 
the adverse clinical consequences of IR-injury is to precondition the cells to 
become more tolerant against a sustained ischemic bout. The following section 
will detail the mechanisms of ischemic preconditioning and its capacity to reduce 
injury caused by ischemia and reperfusion. 
 
The Protective Effects of Ischemic Preconditioning 
Although there are many implications of IR-injury there are various 
therapeutic methods that have shown benefits to decrease the impact and size of 
injury; one of these methods is IPC. This was first observed as a result of an 
original experiment by Murry et al., who showed a reduction in myocardial infarct 
size in canine hearts after the application of a preconditioning stimulus via 
occlusion of the circumflex coronary artery.24 Because of this study, the concept 
of IPC was introduced by these authors in 1986. In this experiment, the 
circumflex coronary artery was exposed to four 5 minute occlusions, each 
separated by 5 minutes of reperfusion, which was then followed by continuous 
ischemia for 40 minutes. They observed a 25% reduction in the myocardial 
infarct size with the IPC stimulus. This study laid the groundwork for many 
subsequent studies showing the protective benefits of preconditioning a tissue 
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locally and remotely. As mentioned previously, most of the damage during IR-
injury occurs during reperfusion and not ischemia. For quite some time it was 
believed that ischemia was responsible for all of the damage and it is now 
understood this is not the case, although the duration of ischemia does 
determine the severity of injury. Bouts of 2-3 low dose ischemic periods, with 
equal periods of reperfusion between each ischemic bout, can induce 
cardioprotective benefits against future IR-injury events by decreasing the 
neutrophil accumulation and apoptosis in turn decreasing the size of myocardial 
infarction.21 The use of IPC therapy prior to a long term ischemic episode, such 
as coronary artery bypass surgeries, is associated with reduced markers of 
myocardial cell death.25  
Local IPC entails the occlusion of tissue or an organ directly at the source, 
for instance cross clamping of the aorta prior to coronary artery bypass surgery, 
which is very invasive and impractical.26 However, compared to local IPC, rIPC, 
which was first proposed in 1993 by Pryklenk et al., provides greater benefits 
since it is less invasive than local IPC. They showed that small episodes of 
ischemia in one vascular bed protected a different area of the myocardium in the 
canine to sustained coronary artery occlusion. These investigators suggested 
that preconditioning was mediated by some unknown factors that were released 
and transported from the preconditioned area to the tissue experiencing IR-
injury.27 An experiment done by McClanahan et al. also in 199328, showed a 
reduction in myocardial infarct size in the rabbit when a preconditioning stimulus 
was applied to the kidneys. In this manner, rIPC was used for inducing protection 
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of a distant organ through a peripheral limb or internal organ. Birnbaum et al. 
showed that cardioprotection against IR-injury was triggered via lower limb 
skeletal muscle IPC.29 Indeed, they showed that occluding blood flow in the 
gastrocnemius muscle resulted in a reduction of myocardial infarct size by 65% 
in rabbit heart. Similarly, Oxman et al. demonstrated that application of rIPC to 
the hind limb of rats using a tourniquet prevented reperfusion arrhythmias.30 The 
occlusion of a limb simply requires a tourniquet or inflatable cuff and is beneficial 
for patients undergoing any type of surgery. This method’s protocol is similar to 
local IPC in that three 5 minute ischemic periods, intermittent with 5 minute 
reperfusion periods transpire; however rIPC occurs on a limb distal from the 
target organ. The resultant mechanisms are unclear but it is believed that the 
mechanisms are paralleled with mechanisms produced by local IPC; but include 
additional signal transduction pathways.31 A few theories exist relating to how 
rIPC is accomplished; for instance, the neural theory suggests that endogenous 
substance produced in the ischemic limb activates a local afferent pathway which 
activates an efferent pathway. The humoral theory proposes that the remote limb 
releases substances into the blood carrying it to other organs triggering 
intracellular pathways that mediate protection. Finally, the inflammatory 
suppression theory suggests that rIPC suppresses apoptosis and inflammation in 
cells reducing the systemic inflammatory response and buffers against ROS.31 
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Impact of Cardiovascular Risk Factors on IR-injury and Preconditioning 
It is believed that the cardioprotective benefits of ischemia preconditioning 
are reduced in the presence of cardiovascular risk factors.32 Unfortunately, a 
majority of the population who are in need of IPC possess one or more 
cardiovascular risk factors. Currently, there are numerous animal studies that 
predominately show that risk factors diminish the protective effects of ischemic 
conditioning. However, some of these studies show conflicting findings. Today, 
there is only one human study that tested local ischemic preconditioning in the 
presence of one cardiovascular risk factor (aging). The following paragraphs will 
describe the literature, to date, on the effects of cardiovascular risk factors on 
ischemic preconditioning. Of the studies that follow, it is important to note that 
they only investigated local ischemic conditioning; no studies have investigated 
remote ischemic conditioning. 
 
Hyperlipidemia/Hypercholesterolemia 
Many animal studies have been completed in regards to how 
hypercholesterolemia impacts the effects of IR-injury on the myocardium. Studies 
conducted on animals with experimentally-induced hypercholesterolemia have 
found negative responses to IR-injury; for instance, these animals experienced 
greater infarction size, increases in troponin T release, or greater amounts of 
cellular apoptosis.33-36 These studies confirm that hypercholesterolemia or 
hyperlipidemia show a noteworthy magnification of myocardial IR-injury. 
However, some animal studies have found opposing results, either 
18 
 
 
hypercholesterolemia has no effect on the outcome of IR-injury or it may make 
the heart more resilient. For example, studies have found reduced myocardial 
infract size, reductions in cardiac contractile function, or cardiac functional 
parameters were not impaired.37-39 Mixed results require more studies in order to 
determine what mechanisms are responsible for infarctions and how 
hypercholesterolemia impacts infarction size and IR-injury.  
In terms of IPC, it has been found that cardioprotective benefits are lost 
when an animal or person has hypercholesterolemia. Most studies, completed on 
animals, concluded that the presence of hypercholesterolemia increased the size 
of myocardial infarction.39,40 Two studies completed on humans found that 
increases in plasma cholesterol and LDL levels reduced the efficacy of ischemic 
preconditioning.41,42 Administering effective therapy cannot be done until it is 
determined how cardiovascular risk factors impact ischemia reperfusion therapy 
and whether or not ischemic preconditioning is effective in these groups. 
 
Hypertension 
Much like hypercholesterolemia, hypertension exacerbates the negative 
effects caused by myocardial/endothelial IR-injury. Studies have found that, 
because of hypertension, the myocardium is at greater risk of 
electrophysiological disturbances and sustaining injury after IR-injury.32 Animal 
studies have found that the myocardium experiences earlier rigor contracture, 
depressed contractile function, and depressed lactate dehydrogenase.43-46 The 
increased sensitivity of the myocardium created by hypertension is believed to be 
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attributed to the mechanisms of IR-injury discussed previously, such as changes 
to ATP production, the mitochondria, glycolytic metabolism, pH level, and 
increased ROS/decreased antioxidants.47-51 Much like hypercholesterolemia, 
hypertension decreases the benefits of ischemic preconditioning.  
 
Diabetes 
Diabetes is yet another cardiovascular risk factor that impacts the severity 
of myocardial IR-injury, as well as decreases the benefits of IPC. Along with the 
previous cardiovascular risk factors mentioned, a person with type I or type II 
diabetes will experience an increase of myocardial infarction after IR-injury. 
Interestingly, some studies conducted on animals found that animal hearts were 
more resistant to IR-injury for the first couple of weeks after the animal was 
induced with diabetes. However, these benefits decreased dramatically after two 
weeks.52 As expected, many clinical studies have found debilitating and deadly 
impacts caused by diabetes in animals as well as humans. Studies have shown 
increases in mortality for diabetic people and even greater occurrences of 
mortality with women.53-55 Much like other cardiovascular risk factors, people with 
type I or type II diabetes will not receive the traditional benefits of IPC; such as 
reduced infarction size, arrhythmias, or contractile dysfunction.56   
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Aging  
Aging is yet another cardiovascular risk factor that is unfortunately 
untreatable and unavoidable. While many preclinical animal models clearly show 
reduced efficacy of ischemic conditioning strategies and more severe myocardial 
IR-injury in aged hearts 57,58, only one human study has been completed that has 
tested how IPC affected IR-injury between young and older men.9 The study 
consisted of 15 healthy and recreationally active young (20-25 years) and older 
(68-77 years) men who completed two sessions that were randomized to a sham 
or experimental protocol. During each session, the subjects completed a local 
preconditioning protocol that consisted of three 5 minute bouts of ischemia, at 20 
mmHg (sham) or 200 mmHg (experimental), intermittent with 5 minutes of 
reperfusion. Upon completion of local IPC, the subjects underwent 20 minutes of 
IR-injury. Ischemic preconditioning and IR-injury protocols were completed on 
participants’ right upper arm and flow mediated dilation (FMD) measurements 
were attained on the right hand. Flow mediated dilation measurements were 
completed before and after local IPC and IR-injury to determine how IPC affected 
IR-injury. The results showed that the young men benefited from IPC while the 
older group did not. The young men’s FMD after IR-injury resulted in a 2% 
decrease from baseline measurements, whereas their FMD did not decrease 
following IR-injury preceded by local IPC. The older men experienced a 
significant decrease in FMD after completion of each protocol; which supports 
the belief that local IPC benefits are reduced in the older population or presence 
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of cardiovascular risk factors. As the authors of the study noted, the older 
population is the group who would typically need IPC.59  
 
Literature Review Summary 
Clinically, IR-injury is a common and unavoidable occurrence that results 
in further injury to the affected tissue or organ. Ischemic reperfusion injury can 
affect all organs and tissue, including the endothelial layer of the vasculature and 
triggers a variety of mechanisms that lead to further cell damage; ultimately 
leading to cellular death or possibly morbidity. Adenosine triphosphate depletion, 
Ca2+ overload, oxidative stress, and coagulation generate an unsteady 
environment that attribute to multiple consequences of IR-injury, such as 
arrhythmias or myocardial stunning. A variety of therapies have been studied, 
such as IPC which has been found to diminish infarction size, arrhythmia 
occurrence, and stunning. Unfortunately, by and large, preclinical animal models 
with experimentally-induced cardiovascular risk factors appear to aggravate IR-
injury as well as diminish the benefits typically provided by IPC. However, there 
are very limited human studies on this issue, which underscores the urgent need 
to identify how these risk factors alter endothelial protection in people who are a 
greater risk of IR-injury.  
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CHAPTER 3  
METHODS 
The present study was conducted by Ms. Tiffany Trachte, a graduate 
student in the Department of Health & Nutritional Sciences at South Dakota State 
University under the mentorship of Dr. Gary Van Guilder. This section will outline 
the methodology for the present study.  
 
Specific Aim: To determine the influence of increased cardiovascular risk 
burden on the capacity of rIPC to protect against endothelial IR-injury. 
 
Subjects and Eligibility Screening: Twenty-two age-matched (12 women/10 
men) adults between the ages of 20-79 years were studied [11 with lower risk 
burden, 11 with raised burden]. Sample size was established based on a recent 
human study in adults with advanced age that demonstrated significantly 
reduced protection of local arm IPC in 15 older men and women.9 Research 
subjects who expressed interest in volunteering for the study were screened for 
eligibility using a medical history form. Screening was conducted either on the 
phone, via email, or in person. Individuals that met eligibility requirements 
underwent the informed consent process and baseline measurements to 
determine the presence or absence of cardiovascular risk factors and 10-year 
cardiovascular disease risk score (described below). Inclusion and exclusion 
criteria are shown below. 
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Inclusion Criteria 
 Any race or ethnicity 
 Men and women between the ages of 20-79 years 
 Apparently healthy with no history or evidence of cardiovascular, 
pulmonary or metabolic disease 
 Non-medicated and not taking any vitamin supplements or energy drinks 
 Non-smoking 
 Sedentary 
 
Exclusion Criteria  
 History or evidence of cardiovascular, pulmonary or metabolic disease 
 Participating in 3 or more days of ≥30 minutes of aerobic exercise for the 
past 3 months 
 Currently pregnant, recent pregnancy, or women taking oral 
contraceptives 
 Infected or wounded index fingers 
 
Criteria to Identify Cardiovascular Risk Burden: Cardiovascular disease risk 
factors were established according to the ethnic-specific International Diabetes 
Federation definition and risk classification established by the American Heart 
Association.60,61 Research subjects were categorized into a raised risk burden or 
a lower risk burden group.  
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Raised risk burden: Subjects in the raised risk burden group will demonstrate 
with ≥3 of the following risk factors: 
 Family history (myocardial infarction, coronary revascularization, or 
sudden death before 55 year in father or other male first-degree relative or 
before 65 year in mother or other female first-degree relative 
 Ethnic-specific BMI classification of obese or abdominal obesity (defined 
as waist circumference with ethnic-specific criteria) 
 Dyslipidemia (defined by one of the following): 
o total cholesterol ≥200 mg/dl; 
o fasting triglycerides ≥150 mg/dl; 
o high-density lipoprotein cholesterol <40 mg/dl in men or <50 mg/dl in 
women; 
o low-density lipoprotein cholesterol ≥130 mg/dl 
 Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 
mmHg; 
 Prediabetes as defined by a fasting blood glucose ≥100 mg/dl 
 
Lower risk burden: Subjects in the lower risk burden group will demonstrate with 
sedentary status and less than ≤2 other risk factors.  
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Baseline Measurements to Determine Cardiovascular Risk Factors  
 
Metabolic measurements 
Following an overnight fast, a small drop of blood was taken from the 
index finger and analyzed for fasting cholesterol and blood sugar concentrations 
using the Cholestech LDX System (Alere Inc., Waltham, MA, USA). Thereafter, 
resting blood pressure, body height, weight, waist circumference, and percent 
body fat was completed using established procedures.62 
 
Blood Pressure measurements 
Non-dominant arm auscultatory resting systolic and diastolic blood 
pressure was measured using an appropriately sized stethoscope and 
sphygmomanometer (Diagnostic 700 Series, American Diagnostic Corp, 
Hauppauge, NY) following 5 minutes of seated quiet rest using standard 
procedures. Resting blood pressure measurements were performed twice and 
separated by 3 minutes and averaged. Resting heart rate was measured using a 
60 second radial pulse count.  
 
Anthropometric measurements 
Standing height and body weight was measured with a digital scale (Seca 
876 digital scale, Seca Corporation, Hamburg, Germany). Abdominal waist 
circumference was assessed with a Gulick tape measured at the smallest part of 
the abdomen, above the umbilicus and below the xiphoid process to the nearest 
26 
 
 
0.1 cm at the end of normal expiration using standard procedures. Waist 
measurements were completed twice and averaged. Percent body fat was 
estimated by air displacement plethysmography (BODPOD, COSMED USA Inc., 
Illinois). Body mass index (BMI) was calculated as weight (kg) divided by height 
(m2).  
 
Determination of 10-year Cardiovascular Disease Risk 
Traditional cardiovascular risk factors (age, sex, total cholesterol, HDL-
cholesterol, smoking status, and systolic blood pressure) were applied to the 10-
year Framingham risk score to estimate future CVD risk.63 We utilized the 
ACC/AHA 2013 Cardiovascular Risk Calculator, which predicts a first 
atherosclerotic vascular event including a myocardial infarction and stroke.61 
 
Experimental Design: The experiment utilized a 2×2 factorial randomized 
crossover design. There were two independent variables (IV), each with two 
levels. IV1 was the risk burden group (low burden versus raised burden). IV2 was 
the conditioning group (rIPC versus a sham control).  
 
Experimental Procedures (rIPC or sham): Following eligibility screening, informed 
consent procedures, and enrollment, 22 subjects were randomized to participate 
in two sessions of microvascular endothelial function in response to endothelial 
IR-injury in the absence and presence of rIPC (figures 1 and 2). These sessions 
occurred at least 1-2 weeks apart.  
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Measurement of Microvascular Endothelial Function 
Endothelial function, an essential component of cardiovascular health, 
was measured with a non-invasive technique known as digital pulse arterial 
tonometry (EndoPAT 2000, Itamar Medical Inc.), an FDA–approved technique 
consisting of an index fingertip sensor probe that detects microvascular volume 
changes with each pulse. This volume change can be detected to provide an 
indication of reactive hyperemia, which is a well-established marker of 
endothelial vasodilator function. The amplitude of each arterial pulse can be 
quantified and analyzed by an automated, proprietary computer algorithm and 
tracked over time during the experiment. This test was administered in a supine 
position in a comfortable, quiet room. It consists of three, 5-minute phases:  
 
Phase 1: baseline 
 
Phase 2: Short-term occlusion of blood flow 
 
Phase 3: Rapid return of blood flow (reactive hyperemia) 
The amplitude of changes in finger volume is proportional to arterial 
dilation, a well-established predictor of endothelial function.64 An air-filled finger 
cuff was positioned on the index finger of each hand and set by the computer to 
inflate to 10 mmHg below diastolic blood pressure (about 70 mmHg). The finger 
cuff contains sensors that detect changes in finger volume with each heartbeat 
pulse. After 5 minutes of baseline data acquisition, a blood pressure cuff was 
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inflated on the left upper arm to 220 mmHg for 5 minutes to occlude blood flow to 
the arm and hand. After 5 minutes of arm occlusion, the blood pressure cuff was 
deflated and measurement of the change in fingertip volume was assessed for 5 
minutes. The total duration of the assessment of microvascular endothelial 
function was 15-20 minutes.  
After baseline assessment of endothelial function and subsequent to a 15 
minute washout period, participants underwent either the rIPC or the sham trial. 
A high pressure cuff placed on the right upper arm was inflated to 220 mmHg 
(EC20 rapid cuff inflator, DE Hokanson, Inc., Bellevue, WA) for 5 minutes, 
followed by 5 minutes of reperfusion to induce rIPC.65 This procedure was 
repeated 3 times. Thereafter, the left arm underwent endothelial IR-injury by 
inflating the high pressure cuff to 220 mmHg for 20 minutes, followed by 40 
minutes of reperfusion. Assessment of endothelial function was repeated 
following 40 minutes of reperfusion. The total time to perform this experiment 
was approximately 3 hours. The sham control was identical to the rIPC trial 
except the pressure cuff inflated to 15 mmHg only to avoid preconditioning. 
 
 
Timeline: Upon IRB approval, enrollment and data collection procedures began 
in earnest in September 2015 and continued through the spring 2016 semester. 
All data collection procedures were completed by March 2016. 
  
29 
 
 
Statistical Analyses 
The RHI was expressed as the post-to-pre occlusion PAT signal ratio in 
the index finger following 5 min of left brachial artery ischemia, relative to the 
same ratio in the contralateral non-occluded control arm, corrected for baseline 
vascular tone of the occluded arm. Subject characteristics were determined by 
one-way ANOVA. The Mann-Whitney U test was used to determine differences 
in the number of risk factors between groups. Data was checked for normality 
and spread. Measures of central tendency were used to calculate baseline 
subject data. The primary outcome was the difference in remote IPC-mediated 
endothelial protection between lower and raised risk burden groups. Repeated 
measures analysis of variance was used to determine differences in endothelial 
function before and after ischemic preconditioning. Non-parametric statistics was 
used if data did not meet assumptions of parametric analysis. Statistical 
significance was set at P<0.05. Missing data was coded with ‘-9’ and not used for 
analyses. Attempts were made to obtain missing data prior to data analysis. 
Linear regression was used to establish correlations between risk factors and the 
RHI response in the total sample. Data are means± SD unless otherwise noted. 
Data were analyzed with IBM SPSS Statistics version 23 (Armonk, NY). 
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CHAPTER 4  
RESULTS 
  Twenty-two subjects (12 women, 10 men) volunteered to participate in this 
study between September 11, 2015 and March 1, 2016. Upon determination of 
cardiovascular risk factor classification, subjects were categorized into lower 
burden (≤2 risk factors) and raised burden risk groups (≥3 risk factors). Due to 
conflicting schedules and/or time constraints two of the subjects withdrew from 
the study. Among the remaining 20 subjects, 13 completed both the sham and 
remote ischemic preconditioning sessions while 7 subjects completed only the 
remote ischemic preconditioning session. A majority of the subjects were 
comfortable with the rIPC and IR-injury procedures. Upon completion of IR-injury, 
typical statements made by subjects were their forearms and hands felt as if 
“they were wearing a glove”, “like extreme pins and needles”, or “heavy”.  
Table 1 displays means with standard deviation of subject characteristics 
in the lower burden and raised burden risk groups. Age was similar in mean and 
range; the age of the 3 men and 9 women in the lower burden group ranged from 
25-59 years; while the 7 men and 3 women in the raised burden group ranged 
from 25-68 years. Body mass (P=0.029), waist circumference (P=0.011), and 
blood pressure (P=0.001) were greater in the raised burden subjects. Each 
subject within the lower burden group had systolic and diastolic blood pressure 
measurements within the normal range, whereas blood pressure in the raised 
burden group were prehypertensive or hypertensive. Triglycerides were the only 
lipids to show a significant difference (P=0.039) between groups. Interestingly, 
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the fitness tests resulted in a statistically significant difference (P=0.044) in which 
the raised burden subjects measured a higher mean VO2max compared to the 
lower burden subjects. 10-year Framingham risk score (P=0.12) and the 
ACC/AHA CVD risk factor score (P=0.06) were higher in the raised burden  
subjects. 
Table 2, below, displays the number of subjects within each 
cardiovascular risk factor category. As expected, the number of risk factors, 
particularly obesity, elevated blood pressure, high LDL, and elevated triglycerides 
were significantly higher in the raised burden group. The most prevalent risk 
factor in the raised burden group was obesity.   
Table 1. Subject characteristics 
Variable 
Lower Risk 
Burden 
(n=12) 
Raised Risk 
Burden 
(n=10) 
 
Age, year 45 ± 13 47 ± 16  
Sex, M/W 3 / 9 7 / 3  
Body mass, kg 78 ± 14 103 ± 33*  
BMI, kg/m2 27 ± 4 33 ± 10  
Body fat, % 38 ± 8 38 ± 11  
Waist circumference, cm 84 ± 8 107 ± 26*  
Systolic BP, mmHg 108 ± 8 130 ± 18*  
Diastolic BP, mmHg 66 ± 9 84 ± 14*  
Total-cholesterol, mmol/L 4.5 ± 0.9 4.9 ± 1.4  
LDL-cholesterol, mmol/L 2.6 ± 0.8 3.0 ± 1.0  
HDL-cholesterol, mmol/L 1.6 ± 0.5 1.3 ± 0.5  
Triglycerides, mmol/L 0.8 ± 0.4 1.5 ± 0.9*  
Glucose, mmol/L 4.9 ± 0.4 5.2 ± 0.9  
VO2max, ml/kg/min 34 ± 3 41 ± 9*  
10-year Framingham Risk Score, % 0.59 ± 0.2 2.6 ± 4.1   
ACC/AHA CVD RF score, % 0.64 ± 0.5 3.0 ± 3.9  
Values are means ± SD. M, men; W, women; BMI, body mass index; BP, 
blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 
VO2max, maximal oxygen uptake; *P<0.05 
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Table 2.  Risk factor distribution within each group. 
Aging 
#(%) 
Family 
history 
#(%) 
Obesity 
#(%) 
Elevated blood 
pressure 
#(%) 
High total 
cholesterol 
#(%) 
High LDL 
#(%) 
Low HDL 
#(%) 
Elevated 
triglycerides 
#(%) 
Prediabetes 
#(%) 
Total 10 (46) 5 (24) 15 (68) 6 (27) 6 (29) 6 (29) 6 (29) 4 (19) 1 (5) 
Lower 
Burden 
4 (33) 1 (9) 5 (23) 0 (0) 2 (18) 1 (9) 2 (18) 0 (0) 0 (0) 
Raised 
Burden 
6 (60) 4 (40) 10 (45)* 6 (100)* 4 (40) 5 (50)* 4 (40) 4 (40)* 1 (10) 
LDL, low-density lipoprotein; HDL, high-density lipoprotein. *P<0.05 vs. low burden. 
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 Table 3 shows the number of risk factors present in the combined sample 
and between lower and raised burden subjects. As expected, the raised burden 
group exhibited more risk factor clustering with 75% of the subjects having at 
least 3 risk factors.   
 
Table 4, below, displays the changes in heart rate and blood pressure 
measurements during the microvascular function protocol between the lower 
burden and raised burden risk groups. The lower burden group’s systolic and 
diastolic blood pressure measurements were consistent throughout the protocol. 
There was a significant main effect (P=0.028) of diastolic blood pressure across 
time in the raised burden group.  
Table 3. Distribution of cardiovascular risk factors in the sample population.  
Risk factors 
Total 
# (%) 
Lower Risk 
Burden 
# (%) 
Raised Risk 
Burden 
# (%) 
0 4 (18) 4 (33) 0 (0) 
1 2 (9) 2 (17) 0 (0) 
2 6 (27) 6 (50) 0 (0) 
3 3 (14) 0 (0) 3 (30) 
4 5 (1) 0 (0) 5 (50) 
5 1 (5) 0 (0) 1 (10) 
6 0 (0) 0 (0) 0 (0) 
7 1 (5) 0 (0) 1 (10) 
Risk factors included age (men ≥45 yr, women ≥55 yr); family history (first-
degree male <55 years of age or first-degree female <65 years of age suffering 
from a heart attack, heart disease, or death); BMI  ≥30 kg/m2; systolic blood 
pressure ≥130 mmHg and/or diastolic ≥85 mmHg; high total cholesterol ≥200 
mg/dL; high LDL-cholesterol ≥130 mg/dL; low HDL-cholesterol (women <50 
mg/dL, men <40 mg/dL); triglycerides ≥150 mg/dL and glucose ≥100 mg/dL. 
Data represent sum (relative %). 
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Table 4. Changes in heart rate and blood pressure during the microvascular function protocol with remote 
preconditioning. 
 
Lower Risk Burden Raised Risk Burden 
 
Rest 30 min 55 min 95 min 
105 
min 
Rest 30 min 55 min 95 min 
105 
min 
Heart rate, bpm 66±13 61±9 63±8 61±10 60±10 64±8 63±9 64±10 66±10 61±9 
SBP, mmHg 112±9 115±12 112±11 112±14 113±12 129±20 132±15 132±19 141±16 134±13 
DBP, mmHg 67±7 68±7 65±9 65±8 66±7 77±15* 80±14* 78±16 84±14 80±14 
Data represent mean±SD. *P<0.05; the difference lies between rest and 30 min measurements with the 95 min 
measurement.   
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Figure 1 displays the reactive hyperemia index (RHI) at baseline and 
following endothelial IR-injury in the 13 (8 lower burden, 5 raised burden) 
subjects that completed the sham trial. Both groups displayed a small reduction 
in RHI following endothelial IR-injury, although this was not statistically 
significant.  
 
Figure 1. Reactive hyperemia index at baseline and after endothelial IR-injury 
during sham session without rIPC. 
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Figure 2 displays RHI at baseline and with endothelial IR-injury in the 
presence of rIPC, for both lower and raised risk burden groups. There were no 
significant group differences in RHI at baseline. However, the RHI after 
endothelial IR-injury showed a significant difference (P=0.007) between the lower 
and raised burden groups. Following rIPC and endothelial IR-injury, the RHI for 
the lower burden group increased by 23% (P=0.072). On the other hand, despite 
rIPC the raised burden group experienced a 25% reduction (P=0.05).  
 
Figure 2. Effects of rIPC on RHI at baseline and after endothelial IR-injury in the 
lower and raised burden groups. *P=0.05 vs. baseline in raised risk burden 
group. †P=0.007 vs. corresponding trial in lower burden.  
 
  
Baseline 
IR-injury with remote ischemic preconditioning  
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Lower Risk Burden Raised Risk Burden
R
e
a
ti
v
e
 H
y
p
e
re
m
ia
 I
n
d
e
x
͙
͙
†
*
37 
 
Figure 3 displays the baseline pulse wave amplitude across 300 seconds 
during hyperemia between groups. There were no significant differences 
between groups throughout the 5 minutes of post-occlusion. However, there was 
on average a 25% decrease in reactive hyperemia across each 30 second 
interval in the raised burden group. 
Figure 3. Reactive hyperemia index at 30 second intervals before endothelial IR-
injury between lower and raised burden groups. 
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Figure 4 displays the RHI across 300 seconds following endothelial IR-
injury with rIPC in both groups. While both groups demonstrated significant 
increases in reactive hyperemia across time, there was a marked difference 
between groups (P=0.028). Notably, between the time interval from 30-150 
seconds, the reactive hyperemia response was, on average, 63% lower for the 
raised burden subjects following endothelial IR-injury despite remote 
preconditioning.  
 
Figure 4. Reactive hyperemia index following endothelial IR-injury at 30 second 
intervals with remote ischemic preconditioning between the lower and raised 
burden groups. P<0.05 vs. raised burden. 
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 Figure 5 displays the association between cardiovascular risk factors and 
the RHI in the presence of rIPC (left) and the percent change from baseline 
(right) after endothelial IR-injury. There was a significant correlation between the 
number of risk factors and the RHI after endothelial IR-injury with 
preconditioning, such that those with a greater risk burden demonstrated a 
reduced response with preconditioning.   
 
Figure 5. Reactive hyperemia index and percent change from baseline, with 
rIPC, after endothelial IR-injury in association to number of cardiovascular risk 
factors. 
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CHAPTER 5  
DISCUSSION 
 The main finding of this study supports the hypothesis that subjects with a 
greater risk factor burden did not demonstrate microvascular protection from 
endothelial injury with remote ischemic preconditioning compared to subjects 
with a lower risk factor burden. The novel results present the first direct evidence 
to demonstrate that subjects with raised CVD risk burden showed a reduced 
capacity of remote ischemic preconditioning to resist microvascular endothelial 
injury. These findings suggest that patients in need of coronary revascularization 
may not benefit from remote ischemic conditioning interventions if they present 
with clustered risk factors. Additional research is needed to identify strategies to 
recapture the cardioprotective effects of preconditioning in such patients.  
To date, it is unclear how remote ischemic preconditioning provides 
cardioprotection but ongoing studies are researching the potential mechanisms. 
It is thought that a combination of neural and humoral pathways releasing 
bradykinin, adenosine, and opioids, which then circulate throughout the body 
produce a protective systemic effect against ischemic injury and reperfusion 
injury.66 It is believed that these factors in turn activate intracellular signaling 
pathways on the target organ which then initiate protection by upregulating cell 
survival proteins.66 Much effort has been completed to understand which 
mechanisms and signaling pathways are responsible for the protective elements 
of ischemic preconditioning. Two pathways have been proposed to be associated 
with remote ischemic preconditioning, the reperfusion injury salvage kinase 
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(RISK) pathway and the survivor activating factor enhancement (SAFE) pathway. 
Each pathway is trigged by either adenonsine, bradykinin, opioids, or tumor 
necrosis factor (TNF-α). These effectors then bind to and activate their respective 
cellular receptors which initiates the RISK or SAFE pathways. The cascade from 
the RISK pathway (accumulation of protein kinases, activation of anti-apoptotic 
protein kinases (ERK1/2, Akt, PKC-E and PKG) overlaps with the activity from 
the SAFE pathway (activation of JAK-STAT3 cascade) to prevent opening of the 
mitochondrial permeability transition pore.66,67 Understanding the mechanisms 
aids in defining how the interaction of cardiovascular risk factors impact the 
pathways and reduce ischemic conditioning’s cardioprotection. However, as 
research is finding, animal models with hypercholesterolemia, diabetes, obesity, 
and hypertension show that protection from ischemic preconditioning after IR-
injury, is markedly impaired. 
For example, multiple studies have found that hypercholesterolemic 
animal models subjected to IR-injury did not benefit from bouts of rIPC 
established by an increase in infarct size versus the control models.68-70 In an 
effort to determine how hypercholesterolemia diminishes the effects of ischemic 
preconditioning Tang et al. (2005) investigated hypercholesterolemic rats who 
were subjected to 6x4 minute bouts of rIPC. They found that the myocardial 
infarct size was greater in the hypercholesterolemic rats versus the 
normocholesterolemic rats demonstrating reduced rIPC ability. Notably, they 
related the lower levels of tetrahydrobiopterin (BH4) in the hypercholesterolemic 
rats to the reduced capacity of rIPC. This is significant given that BH4 is an 
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essential factor for nitric oxide synthase (iNOS) which is linked to the pro-survival 
pathways inducing rIPC.71  
 In addition, animal models genetically altered with diabetes have shown 
similar results, the incapacity to benefit from rIPC.72,73 Rana et al. (2015) linked 
diabetes to the disruption of numerous cell survival pathways. For example the 
over-activation of glycogen synthase kinase (GSK-3β) can lead to the opening of 
the mitochondrial permeability transition pore increasing permeability of the cell 
and resulting in swelling and cell death.66,74  
Furthermore, evidence exists that advanced aging is associated with the 
attenuation of ischemic preconditioning in human and animal models.59,75,76 
Studies completed by Takayama et al. (2001) and Tani et al. (2001) found that 
middle and advanced aged rats had decreased activation of protein kinase C 
compared to young rats.75,76 Protein kinase C (PKC) is important in that it is an 
anti-apoptotic protein kinase that activates during reperfusion as part of RISK 
pathway. It is responsible for the opening of the mitochondrial KATP which 
facilitates the beneficial effects of ischemic preconditioning.  
In the presence of cardiovascular risk factors ischemic preconditioning 
does not elicit the same benefits compared to healthy control animals.77-79 Some 
studies have found conflicting results, possibly due to the preconditioning 
protocol used or other varying experimental conditions.66 Despite conflicting 
studies, cardiovascular risk factors are associated with altering or eliminating the 
activation of protective signaling pathways which in turn reduce cardioprotection 
elicited by remote ischemic preconditioning. Our results are in line with previous 
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studies that found cardiovascular risk factors have reduced or eliminated the 
protection of ischemic preconditioning. 
Studies continue to show that remote ischemic preconditioning provides 
remarkable protection against ischemic reperfusion injury in the endothelial and 
myocardial tissue of healthy subjects.5,6,65,80 Experimental data indicate that risk 
factors activate enzymatic systems that reduce nitric oxide and increase reactive 
oxygen species.32 These alterations in the endothelium leads to platelet adhesion 
and aggregation, leukocyte adhesion and migration, and smooth muscle cell 
proliferation; damaging endothelial function. In the presence of one or more 
cardiovascular risk factors, exposing a vulnerable endothelium IR-injury 
exacerbates the injury by preventing nitric oxide production, and worsening 
inflammation and oxidative stress.81 In support of this, our findings show that 
subjects with greater number of risk factors demonstrated a worse response to 
rIPC.  
Currently, most research investigating ischemic conditioning is completed 
with healthy animal models that do not translate well or mimic humans in clinical 
settings. This study is novel in that it is the first human study to investigate the 
microvasculature of subjects with clustered cardiovascular risk factors in 
response to IR-injury subjected to rIPC. The importance of translating 
preconditioning from animal models to humans is that most individuals who 
participate in clinical trials or settings possess a clustering of cardiovascular risk 
factors.66 Likewise, it is not yet understood how cardiovascular risk factors affect 
IPC treatments, particularly those that are invoked remotely with a limb.  
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 Although this study was carefully prepared, there were some unavoidable 
limitations. First, due to supply issues, 7 subjects did not complete a sham trial 
which impacted results when looking at responses to endothelial ischemic injury 
without remote ischemic preconditioning. Second, the subjects were 
predominately white Americans and cannot be applied to other ethnic groups. 
Third, adjustments were made to the reperfusion period after ischemic injury. 
Previous research investigating conduit arteries, showed that 15 minutes of 
reperfusion diminished endothelial function. In the present study we learned that 
at least 40 minutes is needed to characterize reperfusion injury in the digital 
microvasculature. Our findings are not able to identify a specific risk factor 
associated with the reduced rIPC response. 
Despite these limitations, this study raised a few questions for future 
studies. This study measured endothelial function within the first window of 
protection provided by ischemic preconditioning, when the benefits are the most 
robust but for a shorter time span. Future studies could investigate how the 
second window of protection, when benefits are weaker but occur for a longer 
period of time, affects IPC in the presence of cardiovascular risk factors. Also, 
medications were not included in this study therefore future research could 
investigate a combination of treatments; ischemic preconditioning with 
medication in the second window for instance. Another variation of this study 
would be altering the traditional rIPC 3x3 protocol to more or longer bouts of 
ischemia.  
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In conclusion, the results of this study are consistent with prior preclinical 
studies and one clinical aging study, showing that rIPC may be reduced in the 
presence of cardiovascular risk factors. Before this treatment can be applied in 
clinical settings research needs to continue in order to determine how clustered 
cardiovascular risk factors interact with remote ischemic preconditioning. Animal 
models are useful however they do not manifest the risk factors or comorbidities 
typically seen in patients with CVD.82 Research should continue in hopes of 
ascertaining the correct combination of preconditioning strategies that will be 
effective against cardiovascular risk factors, however an international study has 
found that 90% of CVD is caused by 9 risk factors that can be modified through 
diet and exercise.83 In this regard, more emphasis and efforts need to be made 
on educating the public about the importance of exercise and diet in order to 
prevent cardiovascular risk factors and diseases.
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APPENDIX B 
 
Participant Informed Consent Form 
Participation in a Research Project 
South Dakota State University 
Brookings, SD 57007 
Department of Health and Nutritional Sciences 
  
Project Director: Dr. Gary P. Van Guilder Phone No: 605-688-4082 
E-mail: gary.vanguilder@sdstate.edu Date: 06/01/15 
Please read (listen to) the following information: 
  
1.  This is an invitation for you, ______________________________, to participate in a 
research project under the direction of Dr. Gary P. Van Guilder, Director of the Human 
Vascular Protection Laboratory in the Department of Health & Nutritional Sciences. 
2. The project is entitled: Influence of Heart Disease Risk Factors on Ischemic 
Conditioning – Experiment 1 
3.   Ischemic conditioning is a process that helps your blood vessels withstand the physiological 
stress that occurs when blood flow is stopped to a tissue. The purpose of the project is to 
identify how risk factors for heart disease, such as obesity, high cholesterol, or aging, affect 
the ability of ischemic conditioning to protect against this stress. 
4. If you consent to participate, you will undergo 3 research sessions over the course of 3 
months for a total duration of about 8 hours. Each session is described below. 
Session 1 
During the first testing session, we will determine whether you have any cardiometabolic 
risk factors, measure your resting heart rate and blood pressure, body height, weight, waist 
circumference, and percent body fat. You will also undergo a fitness test on a treadmill. 
The time required for session 1 will be ~2 hours. 
Measurement of blood fats and sugars: Following an overnight fast of at least 10 hours, 
we will take a small drop of blood from your index finger using a tiny finger prick to 
measure the amount of fats and sugar in your body. The finger prick will take only one 
second to complete. During this test, you may feel a small prick that may be somewhat 
uncomfortable. After we have obtained the drop of blood, we will clean and place a band 
aid on your finger and provide you with something to eat and drink. 
Measurement of resting heart rate and blood pressure: Following the finger prick 
described above, you will be rest quietly for 5 minutes until we measure your heart rate 
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and blood pressure. Resting heart rate will be measured using a 60 second arterial pulse 
count. To measure your blood pressure, we will place an inflatable cuff around your upper 
arm. We will inflate the cuff to a high pressure. Then we will release the pressure slowly 
while we listen for the sound of your heartbeat. We will repeat this measurement at least 
twice. 
Measurement of body composition: Thereafter, we will measure your height and body 
weight using a digital scale. Abdominal waist circumference will be assessed with a tape 
measured at the smallest part of the abdomen. Percent body fat and muscle mass will be 
estimated by air displacement plethysmography. During this procedure, you will be placed 
in a small enclosed chamber and instructed to sit quietly for 2 minutes. This procedure does 
not require you do anything except sit quietly. 
 
Cardiorespiratory fitness 
If you are over the age of 35, you will undergo the ‘Ebbeling sub-maximal walk test’, an 
8 minute brisk treadmill walk to determine your cardiorespiratory fitness. This walking 
test is suitable for low risk, apparently healthy,middle-aged adults. The first few minutes 
of this test will consist of placing a heart rate monitor and wrist watch on you to measure 
the intensity of the walk. We will then determine a brisk self-selected walking pace that 
equates to 50-75% of your estimated maximum heart rate. The first 4 minutes of the 
walking test will be flat at your self- selected pace. Then, we will increase the ramp of the 
treadmill to 4% grade and you will maintain the same walking speed for 4 more minutes. 
The test will be completed in 8-9 minutes and then we will cool you down for 3 minutes 
at a slow walking speed. 
If you are under the age of 35, you will have the choice to undergo a maximum 
cardiorespiratory fitness test or to complete the walk test described above. The research 
team will discuss with you the test that best suits you. The maximum fitness test will 
measure the amount of oxygen your muscles use while you jog at a moderate to vigorous 
intensity on a treadmill to exhaustion. You will jog at self-selected brisk pace during this 
test. Every 2 minutes, we will increase the incline of the treadmill by 2% until you reach 
your maximum exercise capacity. You will reach your maximum capacity in about 10-
12 minutes. During the exercise test, we will conduct a procedure known as open-
circuit indirect calorimetry, which will allow us to measure your expired levels of oxygen 
and carbon dioxide, your heart rate, and your breathing rate. You will be equipped with via 
a mouthpiece and nose clip to collect your expired air. At the end of the test, we will reduce 
the speed of the treadmill to a brisk walk and reduce the incline to 0% for 3-5 minutes for 
a cool-down period. The criteria to identify whether you reach maximum capacity will be 
based on your heart rate and the amount of oxygen and carbon dioxide that you breathe out 
through the mouthpiece. 
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Sessions 2 and 3 
On a separate testing day, you will be randomized to participate in either the remote 
preconditioning trial or a control trial first. Two weeks after you completed session 2, you 
will be scheduled to complete session 3, the other trial. Each of these trials, described 
below, will last about 3 hours. These trials will be separated by at least 14 days. 
Each of these trials will consist of four parts over the course of 3 hours: 
Part 1: measurement of blood vessel health 
Part 2: remote ischemic preconditioning or control 
Part 3: forearm reperfusion injury 
Part 4: repeated measurements of blood vessel health 
Part 1 - measurement of blood vessel health: One of the main functions of your blood 
vessels is to ensure that all organs and tissues are supplied with adequate blood flow to 
match metabolic demand. The vessel regulates blood flow by dilation (increase volume – 
increase supply) or constriction (decrease volume – decrease supply). With each heartbeat, 
a pulse is produced that increases the volume of blood delivered to your limbs. This volume 
change can be detected to provide an indication of blood vessel health. We will measure 
this volume change using a non-invasive procedure known as digital pulse arterial 
tonometry. This test will involve the use of a small fingertip cuff that detects small changes 
in index figure volume with each pulse beat. The amplitude of each arterial pulse can be 
quantified and analyzed by an automated, proprietary computer algorithm and tracked over 
time during the experiment. This test will be administered while you lie down in a 
comfortable, quiet room. It consists of three,5-minute phases: 
Phase 1: baseline 
Phase 2: Short-term occlusion of blood flow Phase 3: Rapid return of blood flow 
(hyperemia) 
An air-filled finger cuff will be positioned on your index finger of each hand and set by the 
computer to inflate to 10 mmHg below your diastolic blood pressure (about 70 mmHg). 
Because the finger cuff contains sensors that detect changes in finger volume, it is 
important that your fingernails be trimmed to 
obtain the best signal. We will provide nail clippers as needed. After 5 minutes of baseline 
data acquisition, a blood pressure cuff will be inflated on left upper arm to 220 mmHg for 
5 minutes to occlude blood flow to your left hand. After 5 minutes of arm occlusion, the 
blood pressure cuff will be deflated and measurement of the change in fingertip volume 
will be assessed for 5 minutes. The total duration of this measurement will be 15-
20 minutes. You will complete this procedure 4 times during sessions 2 and again during 
session 3. 
Part 2 - remote ischemic preconditioning or control: Preconditioning your muscles has 
been shown to improve the function of your blood vessels and to protect the heart. It can 
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be caused by stopping blood flow to a tissue (e.g. muscle) for very short periods of time 
(i.e., a few minutes) and then letting blood flow back into the tissue for an equal amount 
of time. Stopping blood flow in this manner does not damage the tissue. You will undergo 
preconditioning of your right arm. A pressure cuff will be inflated around your right upper 
arm to a pressure similar to a blood pressure measurement while you rest on a hospital bed. 
Three, 5 minutes high-pressure inflations followed by three, 5 minute deflations will occur. 
We will measure your heart rate and blood pressure during the last minute of each 5 minute 
inflation-deflation cycle. The control trial will consist of the same procedure described here 
except the pressure cuff will be inflated to a low pressure to avoid stopping blood flow 
your arm. 
Part 3 - forearm reperfusion injury: Immediately after part 2, your left arm will undergo 
reperfusion injury by inflating a high pressure cuff to 220 mmHg for 20 minutes, followed 
by 15 minutes of reperfusion. Because arm occlusion is sustained for a longer period during 
this part, you may experience greater discomfort and more intense feelings of numbness of 
the arm, hand and fingers. While most subjects do not report any pain, it is somewhat 
uncomfortable. During the 15 min reperfusion phase, a greater rush of blood in the arm 
will occur and you may feel ‘pins and needles’. 
Part 4 – repeated measurements of blood vessel health: Following forearm injury, we 
will repeat the measurement of your blood vessel health 3 additional times in the final hour 
of the procedure. This measurement is the same as described above under ‘Part 1’. 
5. Participation in this project is voluntary. You have the right to drop out at any time without 
penalty and you have the right not to participate in any aspect of the study. If you are a 
student, your grade for any class will not be affected if you volunteer for this project. You 
will not get extra credit by volunteering for this study. If you have any questions, you may 
contact Dr. Van Guilder at the phone number listed at the end of this form. 
6. There are minimal risks to you if you volunteer for this project. First, blood pressure 
measurements involve inflating an upper arm cuff to a high pressure for 20 seconds. You 
may experience some mild discomfort during this test. Although obtaining a sample of 
whole blood (one drop, or about 40µl) via a small finger prick is safe and confers minimal 
physical risk, there is a chance that you will experience mild pain for a few seconds during 
the procedure. In addition, the finger prick may cause tiny bruising on the skin that should 
subside in a day. With respect to preconditioning your arm, the procedure is quick and 
poses no more than minimal risk to you. Blood flow to your right arm will be stopped for 
5 minutes using a high pressure cuff. As a result, you will experience tight squeezing of 
the arm that may be mildly uncomfortable. Although, generally painless, you may 
experience mild numbness for 5 minutes. Lastly, when the blood pressure cuff is deflated, 
you will experience a rush of blood flow through the right arm. The skin will redden and 
feel warm with transient feelings of ‘pins and needles’ in the skin as blood flow returns to 
normal. These feelings should subside within 2-3 minutes. 
In contrast, forearm reperfusion injury is induced by occluding blood flow to the left arm 
for 20 min, followed by 15 min of reperfusion. This protocol of prolonged arm ischemia 
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followed by reperfusion is a well- established method to show the protective benefits of 
preconditioning in human subjects. Because arm occlusion is sustained for a longer period, 
you may experience greater discomfort and more intense feelings of numbness of the arm, 
hand and fingers. While most subjects do not report any pain, it is somewhat 
uncomfortable. You may also feel that the arm is cold compared with the unaffected arm. 
Finally, the pressure cuff may cause minor bruising to the tissue of the upper arm. Placing 
the pressure cuff over a shirt sleeve will lessen the chance of bruising. During the 15 min 
reperfusion phase, a greater rush of blood in the left arm will occur. Similar to the blood 
vessel health test, the skin will redden and feel warm with transient feelings of ‘pins and 
needles’ as blood flow returns to normal. Some subjects report mild muscle twitching in 
the fingers and thumb during this phase. 
7.  By volunteering for this study, you will receive a state-of-the-art assessment of your 
vascular health and gain insight into the changes that occur in your blood vessels after a 
period of sustained arm occlusion. Moreover, you will be provided your respective 
cardiovascular risk factor information and your personal data regarding body composition 
and cardiorespiratory fitness at the conclusion of the study. 
8. You will not be financially compensated by volunteering for the project. There is no 
financial cost to you for volunteering for this project. 
9. Your data is strictly confidential. When the data and analysis are presented, you will not 
be linked to the data by your name, title or any other identifying item. To keep your identify 
protected we will assign you a unique alphanumeric code. This code will only be available 
to the research team. The code will link you to the study instead of your name. Your 
information will be kept confidential in a password-protected University computer. Copies 
of data forms will be stored in a locked filing cabinet in the office of Dr. Gary Van Guilder. 
All samples of your blood and DNA will coded using the alphanumeric code that we assign 
to you; they will not be linked to your name, address, or any other personal identifying 
information. All samples will be stored in a secure location in the Department of Health & 
Nutritional Sciences. 
I have read the above and have had my questions answered. I agree to participate in the 
research project. I will receive a copy of this form for my information. 
Participant's Signature _________________________________ Date __________ 
Project Director's Signature _____________________________ Date __________ 
If you have any questions regarding this study you may contact the Project Director, Dr. 
Gary Van Guilder, using the contact information presented below. If you have questions 
regarding your rights as a participant, you can contact the SDSU Research Compliance 
Coordinator at (605) 688-6975 or SDSU.IRB@sdstate.edu. 
Project Director: 
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Gary P. Van Guilder, Ph.D. 
Assistant Professor 
Department of Health and Nutritional Sciences 
South Dakota State University 
Box 2203, Intramural 116 
Brookings, SD 57007 
Phone: 605-688-4082 
Email: gary.vanguilder@sdstate.edu 
This project has been approved by the SDSU Institutional Review Board, Approval 
No.: IRB-1507003-EXP 
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APPENDIX D 
 
Vascular Protection Laboratory 
Department of Health & Nutritional Sciences 
Research Eligibility Screening Form 
 
This Eligibility Screening Questionnaire is necessary to help us understand any potential risks 
associated with your eligibility in participating in a research study. All information you provide is 
personal and confidential.  
 
GENERAL INFORMATION 
Name  
Address  
City  
State  
Zip code  
Phone (home)  
Phone (work)  
Email  
Age   
Sex   
Hispanic Identity   
Race   
Emergency Contact  Phone  
 
MEDICAL DIAGNOSES 
Do you have or have you ever had any of the following? Please check yes or no. 
Condition Yes No Condition Yes No 
Heart attack   Pulmonary disease   
Chest pain   Heart valve problems   
Asthma   Heart murmur   
Anemia   Rheumatic fever   
Cardiovascular 
surgery 
  Phlebitis   
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Currently pregnant   Emboli (blood clot)   
Emphysema   Coronary artery disease   
Diabetes (type 1 or 2)   Stroke   
Cancer   Peripheral artery disease   
Raynaud’s disease   Kidney disease   
 
Please list any additional special conditions.  
   
   
 
 
 
 
Major Risk Factors Yes No 
Not 
sure 
Are you a man over the age of 45 or a woman over the age of 55?    
Are you postmenopausal?    
Has your father or brother experienced a heart attack before age 55?    
Has your mother or sister experienced a heart attack before the age of 65?    
Has your doctor ever told you that you might have high blood pressure? 
  
   
Is your cholesterol above 200 mg/dl?    
Do you have prediabetes (blood sugar ≥100 mg/dl)?    
Are you physically inactive (less than 30 minutes of physical activity on at 
least 3 days/week)? 
   
Do you currently smoke or have you quit smoking in the last 6 months?    
Are you > 20 pounds overweight?    
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- Cardiovascular diseases include cardiac, peripheral vascular or cerebrovascular 
disease 
- Pulmonary diseases include chronic obstructive pulmonary disease, asthma, 
interstitial lung disease, or cystic fibrosis 
- Metabolic diseases includes Type 1 or 2 Diabetes mellitus, thyroid disorders, renal 
or liver disease 
 
MEDICATIONS 
Please list any medications you are currently taking including prescriptions medications 
and over the counter medications, dietary supplements, vitamins, minerals, etc. 
Medication Dose and frequency 
  
  
  
 
Please list any dietary supplements you are currently taking including, not limited to 
vitamins, minerals, energy drinks, weight loss/weight gain supplements etc. 
Dietary supplement Dose and frequency 
  
  
  
SIGNS/SYMPTOMS SUGGESTIVE OF CARDIOVASCULAR AND 
PULMONARY DISEASE 
Yes No 
Pain discomfort (or angina equivalent) in the chest, neck, jaw, arms, or other 
areas that may be due to ischemia (decreased blood flow) 
  
Shortness of breath at rest or with mild exertion   
Dizziness or fainting at rest or with mild exertion   
Orthopnea/paroxysmal nocturnal dyspnea (labored breathing at night or while 
sleeping) 
  
Edema (excessive accumulation of tissue fluid usually in the ankles and lower 
legs) 
  
Palpitations or tachycardia (sudden rapid heartbeat)   
Intermittent claudication (lameness due to decreased blood flow)   
Known heart murmur (abnormal heart sound)   
Unusual fatigue   
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APPENDIX E 
Anthropometric and Hemodynamic Data Sheet 
Vascular Protection Laboratory 
South Dakota State University 
 
Subject ID: Tech: Date: Trial: 
 
 
Variable Value 
Age, year  
Height, cm  
Weight, kg  
BMI, kg/m2  
Obesity status  
Waist circumference, cm  
Hip circumference, cm  
WHR  
WHR status  
Body fat, %  
Resting heart rate, bpm  
Resting blood pressure 1, mmHg / 
Resting blood pressure 2, mmHg / 
Blood pressure classification  
 
58 
 
APPENDIX F 
Maximal Oxygen Consumption Test 
Vascular Protection Laboratory 
South Dakota State University 
Treadmill Protocol Personnel Sheet 
Subject ID  
Age  
Sex  
Weight (kg)  
Personnel 
Metabolic cart  
RPE tech  
Treadmill operator  
Spotter 1  
 
Equipment Needed 
 Parvo Medics Metabolic cart 
 Treadmill 
 Heart Rate Monitor attached and working 
 Rate of Perceived Exertion (RPE) chart 
 Towels 
 Gloves 
Technician Responsibilities of a VO2 Max Protocol 
 Ensure metabolic cart is on for 30 minutes before calibration 
 Prepare correct mouthpiece valves with hose and face mask 
 Measure height and weight before setting-up subject 
 Review medical history, risk classification, and ACSM indications for prior 
medical exam and medical supervision before the subject begins a test 
 Ensure the client/subject has signed an informed consent form  
 Instruct/coach subject about the protocol prior to warm-up and answer their 
questions, if any. 
 Explain the RPE scale to the client 
 Explain to the client how to handle the end of the test – straddle treadmill, light 
cycling on ergometer to facilitate cool-down 
 Ensure client safety by carefully observing the client and monitor the test 
continuously 
 Perform changes to workload according to protocol and communicate with client 
 Measure and record heart rate, RPE, and symptoms on data sheet below. 
 Encourage the client throughout the test 
 Complete post-test cleaning of mouthpiece, hoses, and face mask 
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APPENDIX G 
Ebbeling Sub-maximal Walk Test 
The single stage (8 minutes) treadmill walking test is a submaximal aerobic fitness 
test that estimates VO2max. It is suitable for low risk, apparently healthy, non-
athletic adults 20-59 years of age. The walking pace required throughout the test 
also makes it appropriate for participants who experience problems such as knee 
pain when exercising at a jogging pace. The test can be administered to moderate 
sized groups of participants with low to moderate fitness levels and requires only 
a treadmill and a HR monitor. 
Protocol 
1. Calculate 85% of the client’s age-predicted max heart rate and record below. 
2. Calculate 50-70% of his/her age-predicted max heart rate and record below. 
3. Briefly explain the purpose of the test and how it is conducted to the client. 
4. Obtain a stopwatch or timer. Instruct the participant straddle the treadmill.  
5. When ready, instruct the client to warm up for 4 minutes while walking at 0% 
grade and a speed that corresponds to a heart rate between 50-70% of the 
age-predicted max. The recommended walking speed is from 3.4 to 4 mph, 
although these are highly variable.  
6. Measure radial pulse counts the last 15 seconds of each minute. If heart rate 
is not between 50-70% of age-predicted max after the first minute, adjust the 
speed accordingly. 
7. Following the 4-minute warm-up and after you have determined the appropriate 
walking speed, keep the participant at the same speed for an additional 4 
minutes and while setting the grade to 5%.  
8. Record steady-state heart rate from the average of the final 15 sec of the last 
two minutes at the 5% grade. (Note: to achieve steady-state, the heart rate from 
the last two minutes must not differ by more than 5 bpm. If the rate differs by 
more than 5 bpm, extend the test by an additional minute and record the 
steady-state heart rate for the new final two minutes. i.e., minutes 8 and 9). 
9. At the end of the test, instruct the client to cool down at a slow walk and 0% 
grade for 2-5 min. Monitor and record the heart rate every minute. 
10. Enter steady-state heart rate into the equation below to estimate VO2max 
(mL/kg/min). 
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Interpretation 
VO2max is estimated using the following equation where: 
 
 speed = mph 
 HR = bpm 
 age = years 
 gender = 1 for males and 0 for females 
 
VO2 max = 15.1 + (21.8 x speed) – (0.327 x HR) – (0.263 x speed x age) + (0.00504 x 
HR x age) + (5.98 x gender) 
 
 
 
 
 
 
 
 
EXAMPLE 
Client is a 30-year-old male who walked at 3.6 mph at a grade of 5% with a steady-state 
HR of 159 bpm. 
HRmax = 190 bpm; 
50% HRmax = 95 bpm; 
70 % HRmax = 133 bpm: 
 
Estimated VO2max 
= 15.1 + (21.8 x 3.6) - (0.327 x 159) - (0.263 x 3.6 x 30) + 
(0.00504 x 159 x 30) + 5.98 (1) 
= 43.2 mL/kg/min 
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APPENDIX H 
Ischemic Preconditioning Protocol 
Vascular Protection Laboratory 
 
Subject ID: Tech: Date: Trial: 
 
Phase 
Time 
(min) 
Protocol 
Heart Rate, 
BPM 
Blood 
Pressure, 
mmHg 
Baseline 0 Resting  / 
1 30 min Before rIpre/sham  / 
2 55 min After rIpre/sham  / 
3 95 min 
Immediately after 
Forearm IRI 
 / 
4 105 min 
40 min after 
Reperfusion 
 / 
 
Cuff placement instructions: 
Remote preconditioning cuffs are placed on right arm. Forearm IRI cuff is 
placed on left arm.  Place pressure cuffs snugly on the upper arms as high as 
possible.  
Ischemic preconditioning trial: 
Inflate pressure cuffs to 220 mmHg to cause ischemia for 5 minutes, followed 
by 5 minutes of cuff deflation. Repeat 3 times. Record heart rate and blood 
pressure before and after the preconditioning phase.  
Sham control trial: 
Inflate pressure cuffs to 15 mmHg to avoid ischemia for 5 minutes, followed by 
5 minutes of cuff deflation. Repeat 3 times. Record heart rate and blood 
pressure before and after the sham phase. 
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